This letter refutes the “overdiagnosis” narrative, blaming the stimulant shortage on DEA regulatory failures, clinical constraints, and recognition of historical underdiagnosis.
Gintaras Razaitis, MD
Advertisement
Articles by Gintaras Razaitis, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Andes Hantavirus FAQs: What to Know as Quarantined Cruise Passengers Return Home
2
Rituximab Suppresses Clinical Relapses, MRI Activity in Pediatric MS
3
Cancer’s Hidden Wound: Trauma From Diagnosis Through Survivorship
4
New Therapies Offer Hope for Vitiligo, an Often Misunderstood and Undertreated Disease
5